Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Emergent will retain the biodefense programs, platform technologies, and manufacturing infrastructure
August 6, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Emergent BioSolutions Inc. plans to pursue a spin-off of its Biosciences business into a separate, stand-alone publicly-traded company. The spin-off is expected to create two independent public companies with distinct strategic, operational, and development priorities. The new Biosciences company, to be named at a later date, will focus on novel oncology and hematology therapeutics using its core ADAPTIR platform technology in immuno-oncology. Emergent BioSolutions will continue to operate as a global specialty biopharmaceutical company focused on providing specialty products for civilian and military populations that address emerging public health threats. “The proposed spin-off recognizes that our two operating divisions have evolved into distinct business and investment opportunities. The Biosciences spin-off establishes each as a pure play company with a focused strategy and enables each company to target investors attracted to its business profile,” said Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. “This transaction will allow us to accelerate our growth strategy while enabling the new Biosciences company to invest in novel therapeutics in the highly attractive immuno-oncology field. We expect the spin-off to enhance business focus, better align resources to achieve strategic priorities, and unlock significant value for both companies.” In addition to the ADAPTIR (modular protein technology) platform, the new Biosciences company will consist of certain assets in Emergent’s Biosciences division, including: MOR209/ES414, a bi-specific therapeutic for metastatic castration resistant prostate cancer currently in Phase I development in partnership with MorphoSys AG, and a commercial product portfolio consisting of IXINITY, WinRho, HepaGam B, and VARIZIG. Emergent expects to provide the Biosciences company with a fixed cash contribution of $50 million to $70 million. Additional sources of cash to support R&D investment will include commercial product sales and partnership funding. Emergent will retain the biodefense marketed products and development programs, platform technologies, and manufacturing infrastructure in Gaithersburg, MD and Munich, Germany, cGMP manufacturing facilities in Lansing, MI, Hattiesburg, MS, and Winnipeg, Canada, as well as its CMO fill/finish operations in its Camden site in Baltimore, MD. Emergent’s Bayview Campus in Baltimore will continue to operate as an HHS-designated Center for Innovation in Advanced Development and Manufacturing. Emergent’s Winnipeg manufacturing facility is expected to serve as primary CMO for some products of the Biosciences company under a long-term manufacturing agreement. Emergent and the new Biosciences company will have separate management teams and boards of directors. Mr. Abdun-Nabi will remain in his position and Robert G. Kramer will remain executive vice president and chief financial officer of Emergent. Fuad El-Hibri will remain executive chairman of the board. Marvin L. White will serve as president and chief executive officer of the new Biosciences company. Mr. White is currently a member of Emergent’s board of directors. He is the former chief financial officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as executive director and CFO of Lilly USA, and held other positions in corporate finance at Eli Lilly and Co. “Marvin brings more than two decades of experience as a senior executive of prominent pharmaceutical and healthcare organizations,” said Mr. Abdun-Nabi. “Having worked with Marvin on our board for five years, it is clear that his combination of leadership talents and business acumen will serve the new Biosciences company well as it strives to achieve the promise of its product portfolio and platform technology.” “Having witnessed the development of the biosciences business as an Emergent director, I am excited for the opportunity to grow this business as an independent public company by leveraging its innovative ADAPTIR technology in the highly-desirable immuno-oncology field,” said Mr. White. “I look forward to working with the talented team within the new Biosciences company to advance its unique product candidates for the benefit of patients.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !